ReviewESMO open2025
Promoting equitable access to financial services to end financial discrimination against cancer survivors in Europe: scientific and ethical reasons.
Review in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- EBCC-15 manifesto: Removing age-related barriers to improve equity in breast cancer care.Breast (Edinburgh, Scotland) · 2026Review
- An EHA strategic roadmap for improved care in Europe for AYA patients with malignant and chronic non-malignant hematological diseases.HemaSphere · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer incidence and prevalence of cancer survivors are rising. The European Cancer Information System projects 3.25 million new cases in the EU-27 by 2040 versus 2.74 million in 2022; currently, 23 million people live with a previous cancer diagnosis. Cancer survivors face physical, psychosocial, and economic sequelae. Financial toxicity (FT)-the objective and subjective economic burden of cancer-compromises adherence, quality of life, and survival outcomes. Furthermore, mandatory disclosure of a cancer history when seeking loans or insurance further increases FT. MATERIALS AND
methodsWe carried out a narrative review on FT prevalence, determinants, and interventions, and analyzed national 'right-to-be-forgotten' (RTBF) legislations across EU member states to assess their scientific rationale and economic impact.
resultsFT rates ranged from 41% to 48% for objective burden and from 7% to 39% for subjective strain, even in public health care systems. Socioeconomic vulnerability and incomplete social protection were the most consistent drivers of FT. Eleven trials of early financial navigation produced only modest, short-term improvements. Nine EU countries have enacted RTBF legislations. Common eligibility criteria include a minimum remission period (MRP) of 5-10 years for adults, a universal 5-year MRP for pediatric/adolescent cancers, and shorter MRPs (1-3 years) for very-low-risk entities. A significant variability exists between eligibility criteria across countries. Available data from countries where RTBF has been enforced for a longer period show high acceptance rate of survivors' loan insurance applications with acceptable solvency and minimal strain on the insurance system.
conclusionsFT is a prevalent, preventable aftermath among cancer survivors. Structural frameworks such as RTBF legislation can widen equitable access to credit with no major impact on the insurance market. The European Society for Medical Oncology therefore calls for EU-wide adoption of a unified 5-year MRP for RTBF access and for continuous research on the topic, including development of dynamic risk models to reflect contemporary oncology care while integrating socioeconomic data.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.